Open Access Full Text Article

ubmit your manuscript

http://dx.doi.org/10.2147/DHPS.S1756

🖪 У in 🗖

Dovepress

CORRIGENDUM


67

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]


Muto S, Okada T, Yasuda M, et al. *Drug Healthc Patient Saf.* 2017;9:93–104.

On page 97, 'Discussion' section, lines 10–13, left column, the sentence: 'Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (24.0%), while those who continued on tolvaptan treatment discontinued at a much lower rate (11.8%)' should read: 'Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (26.0%), while those who continued on tolvaptan treatment discontinued at a similar rate (10.6%)'.

On page 101, Figure 6, the number of patients of 'Completed trial' in the TEMPO Extension Japan trial should be revised from 'n=75' to 'n=76', and 'Withdrawal rate' should also be revised from '11.8%' to '10.6%' in the allocated to tolvaptan in TEMPO 3:4 trial. The number of patients of 'Completed trial' in TEMPO Extension Japan trial should be revised from 'n=38' to 'n=37', and 'Withdrawal rate' should also be revised from '24.0%' to '26.0%' in the allocated to placebo in TEMPO 3:4 trial. The correct figure is shown here.



Timing and number of patients with elevated serum ALT or AST



Drug, Healthcare and Patient Safety 2018:10 67-68

Content of the work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. by no php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Drug, Healthcare and Patient Safety

Publish your work in this journal

Drug, Healthcare and Patient Safety is an international, peer-reviewed open access journal exploring patient safety issues in the healthcare continuum from diagnostic and screening interventions through to treatment, drug therapy and surgery. The journal is characterized by the rapid reporting of reviews, original research, clinical, epidemiological and post-marketing surveillance studies, risk management, health literacy and educational programs across all areas of healthcare delivery. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/drug-healthcare-and-patient-safety-journal

68

Dovepress